The pharma industry is always transforming. Scientific and business advances build on achievements from the past, and major breakthroughs reshape the market. Behind the many changes of the last year are the leaders that drive that transformation, and their advances have been prolific.

GLP-1 agonists once primarily used for diabetes shifted to obesity and found runaway success. Advances in gene therapies paved the way to the approval of the first gene editing CRISPR drug. Leaps in oncology such as CAR-T cell therapies are improving with off-the-shelf treatments that could open the manufacturing bottleneck. Emerging AI and machine learning tools are increasingly impacting a wide array of pharma operations.

In the backdrop of this forward momentum, the industry is adapting to the market’s shifting landscape — the biotech sector’s recovery, new pricing regulations brought by the Inflation Reduction Act and the ongoing push to move the needle on equity goals have all shaped that ecosystem.

This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions. Our list salutes leaders who are not only navigating these changes, but at times, forging new paths for others to follow.

These are some of the industry’s most inspiring professionals, honored in 10 distinct categories: Standout Leaders, Clinical Trial Pros, Trailblazers, Patient Champions, Biotech Pathfinders, Cancer Care Visionaries, Cardiometabolic All-stars, Cell and Gene Therapy Pioneers, Rare Disease Warriors, and Tech and AI Wizards.

Here are this year’s PharmaVoice 100 honorees.